A Case Report of Primary Squamous Cell Carcinoma of the Breast

Xiaoli Yao,Huihua He,Jingping Yuan,Feng Yao
DOI: https://doi.org/10.21037/tbcr-20-67
2021-01-01
Translational Breast Cancer Research
Abstract:: Primary squamous cell carcinoma (SCC) of the breast is a metaplastic carcinoma subtype and an especially aggressive tumor with poor prognosis. Here, we present a case of locally advanced primary SCC of the breast. We reported a case of a 32-year-old woman with a palpable lump in the inner quadrant of the right breast. Core needle biopsy was performed and revealed SCC. Immunohistochemistry staining indicated that the patient had estrogen receptor (ER)-positive immunoreactivity, but was negative for both progesterone receptor and human epidermal growth factor receptor 2 (HER2). Magnetic resonance imaging (MRI) found a mass in the right breast just 4.8 cm × 4.3 cm × 3.4 cm in size. We planned neoadjuvant chemotherapy consisting of 4 cycle of nab-paclitaxel and every 3 weeks followed by 4 cycles of epirubicin and cyclophosphamide (EC) every 2 weeks. However, after 3 cycles of EC, the disease progressed, and the chemotherapy agents were switched to nab-paclitaxel and cisplatin. Still, disease progression continued, and the chemotherapy agents were changed once more to apatinib, eribulin, and camrelizumab. As this also did not work, modified radical mastectomy was performed. Postoperative pathology revealed extensive necrosis. Our case did not achieve pathologic complete response after neoadjuvant chemotherapy. We then started local radiotherapy, and then adjuvant tamoxifen treatment of 20 mg/day followed by 6 cycles of capecitabine. No evidence of disease was detected at half-year follow-up.
What problem does this paper attempt to address?